Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine how different behavioral interventions designed to alter food perceptions and behaviors affect brain responses to food, eating behaviors, and body weight.
Do I need to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Implicit Priming for Obesity?
Research shows that interventions targeting implicit biases, like Go/No-Go tasks, can have small positive effects on eating behaviors by altering automatic responses to food. Additionally, attention modification training has been shown to reduce overeating in obese children by training them to focus away from food cues.12345
Is implicit priming therapy safe for humans?
How does the treatment 'Implicit Priming for Obesity' differ from other treatments for obesity?
Implicit Priming for Obesity is unique because it focuses on modifying attentional biases towards food cues, training individuals to unconsciously shift their attention away from food, unlike traditional treatments that may focus on diet or exercise. This approach is based on cognitive bias modification techniques, which have been used in other areas like anxiety and substance abuse, and it targets the underlying mental processes that contribute to overeating.12489
Research Team
Jason R. Tregellas, PhD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for adults aged 18-65 with obesity, defined as having a BMI of 27 or greater. It's not suitable for pregnant individuals or those who cannot undergo MRI scans due to metal or electronic devices in their body.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo weekly behavioral interventions, including active or control implicit priming and a food exposure task, for 12 weeks
Follow-up
Participants are monitored for changes in food intake, body weight, fat mass, and brain responses to food cues
Treatment Details
Interventions
- Active Implicit Priming (Behavioral Intervention)
- Control Implicit Priming (Behavioral Intervention)
- Food Exposure Task (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Aviva Abosch
University of Colorado, Denver
Chief Medical Officer since 2019
MD
Uday B. Kompella
University of Colorado, Denver
Chief Executive Officer since 2015
PhD in Pharmaceutical Sciences
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Executive Officer since 2007
MD, M.A.C.P.
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Medical Officer since 2007
MD, M.A.C.P.